Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) Equity Ratio (2016 - 2025)

Palisade Bio (PALI) has disclosed Equity Ratio for 16 consecutive years, with 0.46 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 34.92% to 0.46 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.46, a 34.92% decrease, with the full-year FY2024 number at 0.69, down 14.47% from a year prior.
  • Equity Ratio was 0.46 for Q3 2025 at Palisade Bio, up from 0.39 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2023 to a low of 2.25 in Q1 2021.
  • A 5-year average of 0.44 and a median of 0.7 in 2024 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: crashed 149.94% in 2021, then skyrocketed 217.25% in 2022.
  • Palisade Bio's Equity Ratio stood at 0.24 in 2021, then skyrocketed by 228.66% to 0.79 in 2022, then increased by 1.69% to 0.81 in 2023, then dropped by 14.47% to 0.69 in 2024, then tumbled by 33.11% to 0.46 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Equity Ratio are 0.46 (Q3 2025), 0.39 (Q2 2025), and 0.65 (Q1 2025).